Reaction
Neuroendocrine Carcinoma Of The Skin reporting signals
As of the last recalculation, Neuroendocrine Carcinoma Of The Skin appears in 963 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is ANTI-THYMOCYTE GLOBULIN (RABBIT) (PRR 43.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Anti-Thymocyte Globulin (Rabbit) | 16 | 43.6 | 43.7 |
| Sirolimus | 19 | 31.1 | 31.1 |
| Bendamustine Hydrochloride | 13 | 23.8 | 23.8 |
| Basiliximab | 12 | 22.3 | 22.3 |
| Bendamustine Hcl | 15 | 21.2 | 21.2 |
| Tofacitinib Citrate | 12 | 20.0 | 20.0 |
| Adalimumab-Fkjp | 40 | 19.4 | 19.4 |
| Doxepin | 9 | 19.4 | 19.4 |
| Adalimumab-Aaty | 39 | 18.5 | 18.5 |
| Tacrolimus Ointment 0.1% | 91 | 17.3 | 17.4 |
| Tacrolimus Extended-Release Capsules | 91 | 17.3 | 17.3 |
| Adalimumab-Adaz | 39 | 16.6 | 16.6 |
| Tacrolimus | 101 | 15.5 | 15.5 |
| Ruxolitinib | 47 | 14.9 | 14.9 |
| Anakinra | 10 | 13.2 | 13.2 |
| Voriconazole Injection | 13 | 13.1 | 13.1 |
| Dronedarone | 6 | 12.8 | 12.8 |
| Obinutuzumab | 8 | 10.6 | 10.6 |
| Vismodegib | 3 | 7.3 | 7.3 |
| Vemurafenib | 4 | 7.2 | 7.2 |